5HT-2c AGONIST LORCASERIN DECREASES CANNABIS SELF-ADMINISTRATION IN DAILY CANNABIS SMOKERS

There are no FDA-approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT-2c agonist, lorcaserin, attenuates cue-induced reinstatement of THC-seeking and self-administration. The goal of this placebo-controlled, counterbalanced, within-subject human laboratory...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Addict Biol
Autori principali: Arout, Caroline A., Cooper, Ziva D., Reed, Stephanie Collins, Foltin, Richard W., Comer, Sandra D., Levin, Frances R., Haney, Margaret
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225547/
https://ncbi.nlm.nih.gov/pubmed/33389797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/adb.12993
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi